2nd AnnualInvitation Only
Pan-Hematology
Clinical Updates 2027
Three days, 74 people, one room.
February 4 to 6, 2027
The Royal Sonesta San Juan, Puerto Rico
Dates
February 4-6, 2027
Three-day program
Venue
The Royal Sonesta San Juan
San Juan, Puerto Rico
Audience
74 by invitation
37 faculty & 37 fellows
Format
10 sessions · 32 talks
Talks, panels + expert discussions
A Curated Room: The People Shaping Practice
Now in its second year, this invitation-only meeting convenes 37 leading hematology KOLs alongside 37 hand-selected fellows and junior faculty, the clinicians defining today’s standards across leukemia, lymphoma, myeloma and myeloid neoplasms, in one room for three days.
The program covers the full spectrum of hematologic malignancy: targeted and frontline AML and MRD, lymphoma classification and cfDNA, modern myeloma strategy and T-cell redirection, MDS and MPN, and ALL, CML and CLL. Every session pairs expert talks with a moderated panel, sustained, close-quarters engagement rather than a lecture hall.
AML & MRDLymphoma & cfDNAMyeloma & T-Cell RedirectionMDS & MPNALL & CAR TCML · CLL · Waldenström’s
Meeting Co-Chairs
Listed alphabetically by surname
Naval Daver
MD Anderson Cancer Center, Houston, TX
Christopher Flowers
MD Anderson Cancer Center, Houston, TX
Elias Jabbour
MD Anderson Cancer Center, Houston, TX
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Noopur Raje
Massachusetts General Hospital, Boston, MA
Faculty Drawn From
MD Anderson · Memorial Sloan Kettering · Moffitt · Emory Winship · Massachusetts General and other leading US cancer centers
74
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
Talks across 8 sessions, each paired with a panel and a case
Pan-Hematology Clinical Updates 2027
Proposed Faculty
Listed alphabetically by surname
Prithviraj Bose
MD Anderson Cancer Center, Houston, TX
Uma Borate
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Andrew Branagan
Massachusetts General Hospital, Boston, MA
Jonathon B. Cohen
Emory Winship Cancer Institute, Atlanta, GA
Naval Daver
MD Anderson Cancer Center, Houston, TX
Daniel DeAngelo
Dana-Farber Cancer Institute, Boston, MA
Harry Erba
Duke University, Durham, NC
Christopher Flowers
MD Anderson Cancer Center, Houston, TX
Guillermo Garcia-Manero
MD Anderson Cancer Center, Houston, TX
Michael Green
MD Anderson Cancer Center, Houston, TX
Christopher Hourigan
Virginia Tech FBRI Cancer Research Center, Washington, D.C.
Anthony Hunter
Emory Winship Cancer Institute, Atlanta, GA
Ghayas Issa
MD Anderson Cancer Center, Houston, TX
Elias Jabbour
MD Anderson Cancer Center, Houston, TX
Nitin Jain
MD Anderson Cancer Center, Houston, TX
Tapan Kadia
MD Anderson Cancer Center, Houston, TX
Hagop Kantarjian
MD Anderson Cancer Center, Houston, TX
Jean Koff
Emory Winship Cancer Institute, Atlanta, GA
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Shaji Kumar
Mayo Clinic, Rochester, MN
Aaron Logan
UCSF Health, San Francisco, CA
Sanam Loghavi
MD Anderson Cancer Center, Houston, TX
Sagar Lonial
Emory Winship Cancer Institute, Atlanta, GA
Neha Mehta-Shah
Washington University School of Medicine, St. Louis, MO
Jae Park
Memorial Sloan Kettering Cancer Center, New York, NY
Krina Patel
MD Anderson Cancer Center, Houston, TX
Daniel Pollyea
University of Colorado Anschutz Medical Campus, Aurora, CO
Noopur Raje
Massachusetts General Hospital, Boston, MA
Lindsay Rein
Duke Health, Durham, NC
David Russler-Germain
Washington University School of Medicine, St. Louis, MO
Gilles Salles
Memorial Sloan Kettering Cancer Center, New York, NY
Surbhi Sidana
Stanford Medicine, CA
Saad Usmani
Memorial Sloan Kettering Cancer Center, New York, NY
Eunice Wang
Roswell Park Comprehensive Cancer Center, Buffalo, NY
William Wierda
MD Anderson Cancer Center, Houston, TX
Amer Zeidan
Yale School of Medicine, New Haven, CT
Joshua Zeidner
UNC School of Medicine, Chapel Hill, NC
Three Days, Ten Sessions
Proposed Agenda
Presentations15 min
Panel Discussions45 min
Coffee Breaks20 min
Industry Supported Expert Discussions45 min
Lunch Breaks50 min
AML & Lymphoma
Ohio State University, Columbus, OH
Session ITargeted AML Updates
ModeratorNaval Daver
Molecular Classification of AML and MDS
Sanam LoghaviMD Anderson Cancer Center, Houston, TX
FLT3 Mutated AML Updates
Eunice WangRoswell Park Comprehensive Cancer Center, Buffalo, NY
IDH Mutated AML Updates
Daniel PollyeaUniversity of Colorado Anschutz Medical Campus, Aurora, CO
Menin Inhibitor Updates
Joshua ZeidnerUNC School of Medicine, Chapel Hill, NC
Panel Discussion
Session IIFrontline AML and MRD
ModeratorNaval Daver
Frontline Intensive Chemotherapy Updates
Harry ErbaDuke University, Durham, NC
Frontline LIT Updates
Tapan KadiaMD Anderson Cancer Center, Houston, TX
MRD Assessment and Targeting in AML
Christopher HouriganVirginia Tech FBRI Cancer Research Center, Washington, D.C.
Panel Discussion
Session IIILymphoma Classification and Biomarkers
ModeratorChristopher Flowers
Applying the New FL Classification to Clinical Care and Trials
Gilles SallesMemorial Sloan Kettering Cancer Center, New York, NY
Trials and Approaches for Mantle Cell Lymphoma
Jonathon B. CohenEmory Winship Cancer Institute, Atlanta, GA
Applications of cfDNA in DLBCL Clinical Care and Trials
Jean KoffEmory Winship Cancer Institute, Atlanta, GA
Panel Discussion
Session IVMolecular and Subtype-Specific Lymphoma Updates
ModeratorChristopher Flowers
Applications of cfDNA in FL Clinical Care and Trials
David Russler-GermainWashington University School of Medicine, St. Louis, MO
Applying LBCL Spatial Classification to Clinical Care and Trials
Michael GreenMD Anderson Cancer Center, Houston, TX
What’s New in CTCL/PTCL
Neha Mehta-ShahWashington University School of Medicine, St. Louis, MO
Panel Discussion
Myeloma, MDS & MPN
Session VModern Multiple Myeloma Strategies
ModeratorNoopur Raje
Novel Diagnostic and Monitoring Tools in MM With a Focus on Targeted Sequencing and MR
Shaji KumarMayo Clinic, Rochester, MN
Early Adoption of T Cell Redirected Therapies: CAR T Cells and Bispecifics
Krina PatelMD Anderson Cancer Center, Houston, TX
Life After BCMA Directed Strategies
Sagar LonialEmory Winship Cancer Institute, Atlanta, GA
Panel Discussion
Session VIMyeloma Toxicities and Special Populations
ModeratorNoopur Raje
Focus on Special Toxicities and Infections in the Era of TCRs
Surbhi SidanaStanford Medicine, CA
Treatment of Special Populations: Plasma Cell Leukemia, EMD, Renal Failure
Saad UsmaniMemorial Sloan Kettering Cancer Center, New York, NY
Update on Waldenström’s Macroglobulinemia
Andrew BranaganMassachusetts General Hospital, Boston, MA
Panel Discussion
Session VIIMDS
ModeratorRami Komrokji
CHIP/CCUS
Uma BorateThe Ohio State University Comprehensive Cancer Center, Columbus, OH
Lower-Risk MDS
Amer ZeidanYale School of Medicine, New Haven, CT
Higher-Risk MDS
Guillermo Garcia-ManeroMD Anderson Cancer Center, Houston, TX
Panel Discussion
Session VIIIMPN
ModeratorRami Komrokji
Myelofibrosis
Prithviraj BoseMD Anderson Cancer Center, Houston, TX
PV and ET
Anthony HunterEmory Winship Cancer Institute, Atlanta, GA
Mastocytosis and Other MPN
Lindsay ReinDuke Health, Durham, NC
Panel Discussion
ALL, CML & CLL
Session IXALL
ModeratorElias Jabbour
Ph+ ALL
Hagop KantarjianMD Anderson Cancer Center, Houston, TX
Ph- ALL
Aaron LoganUCSF Health, San Francisco, CA
CAR T in ALL
Jae ParkMemorial Sloan Kettering Cancer Center, New York, NY
Panel Discussion
Session XCML/CLL
ModeratorElias Jabbour
Frontline Therapy for CML
Daniel DeAngeloDana-Farber Cancer Institute, Boston, MA
Relapse Refractory CML
Ghayas IssaMD Anderson Cancer Center, Houston, TX
Frontline CLL
Nitin JainMD Anderson Cancer Center, Houston, TX
Relapse Refractory CLL
William WierdaMD Anderson Cancer Center, Houston, TX
Panel Discussion
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
